An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms
NCT ID: NCT07078682
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
42 participants
INTERVENTIONAL
2025-08-01
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms
NCT05145257
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT03049735
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT03103087
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
NCT02654054
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT03412890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elix Cycle Balance & Elix Daily Harmony
Participants will receive two investigational herbal supplements daily for 24 weeks.
Elix Daily Harmony
Each morning, 1-2 hours after their first meal, they will mix the following into room-temperature or warm water and consume:
Elix Daily Harmony: 3 droppers full (approximately 2.5 mL) Elix Cycle Balance: 6 droppers full (approximately 5.0 mL)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elix Daily Harmony
Each morning, 1-2 hours after their first meal, they will mix the following into room-temperature or warm water and consume:
Elix Daily Harmony: 3 droppers full (approximately 2.5 mL) Elix Cycle Balance: 6 droppers full (approximately 5.0 mL)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be aged 20-45.
* BMI 18.5 - 24.9 kg/m2
* Self-reported prior diagnosis of uterine fibroids.
* Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
* Self-reported moderate to severe discomfort during menstruation, related to pelvic cramps, bloating, mood swings, or fatigue.
* Self-reported menstrual cramps during their cycle, for the past six months minimum.
* If taking hormonal birth control, has been doing so consistently for at least three months, and experiences a menstrual cycle with a period.
* If taking other oral over-the-counter supplements or herbal remedies, has been consistently taking these for at least three months prior to starting the study, and is willing to maintain this routine for the study duration.
* Willing to refrain from introducing any products or any new forms of medication or supplements for the study duration.
* Willing to refrain from any other dietary supplements or herbal remedies targeting the menstrual cycle during the study period.
* Willing to refrain from any new vaccines during the 6 month period.
* Follows a stable, consistent exercise regimen and are willing, for the duration of the study, to not decrease or increase the amount of exercise in their regimen.
* Agrees to refrain from any lifestyle changes that may affect their menstrual cycle for the duration of the study (for example, getting on or off hormonal birth control, reducing the amount of exercise).
* If using any other interventions, such as massage, chiropractic medicine, or acupuncture, agrees not to increase or decrease the number of these other interventions during the study period.
* Resides in the United States.
Exclusion Criteria
* Does not experience menstrual cramping.
* Follows an extreme diet intervention such as dry fasts, water fasts, or ketogenic diets.
* Anyone who has experienced significant weight loss in the past three months prior to study participation.
* Unwilling to stop the use of any medication or herbal remedies/supplements that can affect the menstrual cycle.
* Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
* Anyone with known severe allergic reactions.
* Anyone with any allergies or sensitivities to any of the study product ingredients.
* Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
* Anyone unwilling to follow the study protocol.
* Has stopped, started, or changed hormonal birth control in the past three months.
* Previous users of Elix Cycle Balance.
* Anyone who is currently a smoker or has been a smoker in the past 3 months.
* Anyone who has been diagnosed with the following conditions: PCOS, Endometriosis, PMDD, Adenomyosis, Hashimoto's thyroiditis, Grave's disease (and any other thyroid disorders), hyperprolactinemia, Cushing's disease, congenital adrenal hyperplasia, anorexia, bulimia, orthorexia, binge eating, any other eating disorder.
* History of endocrine disorders such as thyroid disorder, Type 1 or 2 diabetes, or other.
* History of hypertension, hyperlipidemia, or previous venous embolism.
* Overweight/obesity (BMI \> 25 kg/m2).
* Women with other causes of chronic pelvic pain, including infectious disease, gastrointestinal, psychological disorders, fibromyalgia, and chronic fatigue syndrome.
* Hysterectomy, myomectomy, or bilateral salpingo-oophorectomy or other gynecological medical or surgical treatment in the last 6 months.
* History of an abnormal pap smear.
* History of neoplasia of gynecological origin and/or existence of uterine malformations.
* Chronic urinary tract infections or diagnosed functional gastrointestinal conditions like IBS, IBD, Crohn's disease, or ulcerative colitis.
* Currently partaking in another research study or will be partaking in any other research study for the next 24 weeks, or at any point during this study's duration.
* Consume more than 5 alcoholic drinks per week
* Had a vaccine in the last 3 months
20 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Citruslabs
INDUSTRY
Zenchi, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Citruslabs
Las Vegas, Nevada, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20790
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.